Balancing Efficacy and Gastrointestinal Side Effects Experts generally agree that semaglutide is a breakthrough in the management of type 2 diabetes and obesity due to its efficacy in improving glycemic control and promoting significant weight loss
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function
3, 2025 S.D.N.Y., Case No
Some patients who do not respond well to semaglutide find success with tirzepatide, and our guide on switching from semaglutide to tirzepatide covers what to expect from that transition
